_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
IRMD
Primary Facts
Medical Devices
Name:
-
Sector:
1.00M
Industry:
32.37
CEO:
Ms. Leslie McDonnell
Total Employees:
Small Cap
Our Technological Advancement Rating
Our Rating:
-0.101117099
-1.519607635
Iradimed Corporation (XNAS:IRMD) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
IRADIMED CORPORATION (XNAS:IRMD)
One Month Price Target:
Six Month Price Target :
$32.56
Likely Price in One Year's Time:
Ticker:
$33.53
Likely Trading Range Today Under (Normal Volatility)
$32.59
Price Upper limit ($) :
$34.69
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P92
This week:
$30.18
This month :
$27.47
Other Primary facts
Market Cap:
12.57M
Market Cap Classification:
407.86M
Number of Shares
IPO Date:
D
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-20.08%
$22.57
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$37.84
23.66%
$26.90
$42.53
Medium risk (<10%) entry points
Buy Call
Sell Call
$35.31
Buy Put:
Sell Put:
$22.21
$29.43
$36.31
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Devices
Sharpe Ratio:
IRMD, is amongst the top 40% highest yielding stocks in terms of daily returns
Comparison:
1.51%
0.796450533
Sharpe ratio is 79.65% higher than the industry
Average Returns/Yield of
Medical Devices
Daily returns:
1
Weekly returns:
0.10%
Monthly returns:
0.50%
Yearly returns:
23.96%
Comparison of returns:
0.560287595
Classification:
Average annual returns/yield (last 3 years) is 56.03% above industry average
Results of T-Test of Returns:
IRMD is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.62
Volatility (measured by Standard Deviation)
Daily Volatility:
& ratio is 19.38% higher than the market/S&P 500 average
Weekly Volatility:
3.34%
Monthly Volatility:
7.48%
Yearly Volatility:
14.96%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
65.19%
-32.29%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -32.29% below long-term volatility
Weekly VaR:
-6.77%
Monthly VaR:
-15.13%
How Much Can the price of
Medical Devices
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Very high (>70%)
Worst case (decline):
$24.08
This translates to price declining to:
-26%
This translates to price declining to:
>85%
Severe Crash Probability
-30.27%
What is Value at Risk (VaR)?
Risk Fundamentals
83.02%
IRMD is a 113.63% riskier investment compared to the market/S&P 500 & is 83.02% riskier than Nasdaq (IXIC)
IRMD is a 113.63% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Devices
1.065
Expected beta in 1 year's time:
0.693
Expected beta in 3 year's time:
0.555
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--1.07
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is 0.03% above industry average
Beta Comparison & Analysis
Beta of competitors/peers::
1.032
-0.134
Average Industry Beta:
Beta is -13.38% lower than peers
0.000262403
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
-
-
Alpha provided | Alpha Analysis
Alpha provided:
0.785
1.751
8.604
Analysis of Cost of Capital of
Medical Devices
Equity cost of capital:
Alpha is 860% higher than market/& is unsustainably high
0.000
Unlevered (without debt) cost of capital:
Equity cost of capital is 0.02% above industry mean WACC
Before-tax cost of debt:
10.12%
After-tax cost of debt:
-
Overall debt rating:
-
Weighted average cost of capital (WACC):
-
-
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -2.69% below the industry mean
-94.72%
EPS:
Ten Million Four Hundred Twenty-Five Thousand Six Hundred Thirty Dollars
Expected Annual growth rate of EPS (3Y):
Price to free cash flow ratio is -19.05% lower than the industry
-138.98%
Free cash flow (FCF) per share:
Price to book ratio is -24.15% below the industry mean
Growth rate in R&D investment/expenditure is -200.73% lower than the industry
-
Debt per share
Debt repayment rate in last quarter: 0.00%
EBITDA per share
Each employee generates 1736% more EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Devices
P/E Ratio:
-
P/E Ratio of Competitors/Peers:
33.54
-0.862292254
202.142754
-0.839865643
-
-
P/S (Price to Sales ratio):
$3.57
-0.026872796
P/B (Price to book value ratio):
Price to sales ratio is -2.69% below the industry mean
-
-0.190459676
Net income growth rate (3Y):
Annual revenue growth rate is -94.72% below industry average
-70.22%
Dividend Analysis
Net income growth rate is -70.22% lower than the industry average net income growth rate
Dividend payout rate: 120.47%
$1.00
Previous Dividend: $1.00
Previous adjusted dividend: $1.00
Previous Dividend: $1.00
-
-
Average dividend payment (long-term): $1.00
-
Expected next dividend payment date: 25/05/2022
Expected next dividend record date: 18/05/2022
Expected next dividend declaration date: 05/09/2022
Previous dividend payment date: 24/02/2022
Previous dividend record date: 17/02/2022
Dividend History:
Previous dividend declaration date: 02/07/2022
--$0.00
--$0.00
2022-02-16--$1.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
-76.79%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 2.9 years
Debt to assets ratio:
-66.35%
Net debt to assets ratio:
3.41%
-92.39%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -92.39% below industry average
-
Looking forward:
Debt growth rate:
1.0x
-103.55%
0.00%
Analysis of Key Statistics
Correlation of price movement with the market:
5.860707393
Statistical significance of correlation:
-0.47%
Average Correlation of the industry with the market:
0.219
-53.24%
R Squared (percentage of price movement explained by movement of the market):
0.219
Correlation of price movement with Nasdaq (^IXIC):
0.048
Covariance of price movement with the market:
0.011
Kurtosis
0.021
8.292
Skewness of returns:
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
0.354
Fundamental Analysis & Dupont Analysis of
Medical Devices
Gross Profit Margin Ratio:
34.37M
Operating Profit Margin Ratio:
Net profit margin is -235.99% lower than the industry
-244.99%
Net Profit Margin Ratio:
34.37M
Effective Tax Rate:
4.35%
-0.885502069
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -527.17% lower than the industry
-270.00%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -244.99% lower than the industry
-527.17%
Financial Leverage:
-
Current Ratio:
Return on equity (ROE) is -270.00% lower than the industry
0.62165928
Cash Conversion Cycle (days):
$0.17
-0.010458953
Current ratio is 62.17% above industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is -1.05% below industry average
0.08306662
EBITDA generated per employee:
Each employee generates 8% more revenue than industry average revenue per employee
17.35911643
Profit generated per employee:
$1.01
-419%
Free cash flow (FCF) generated per employee:
Each employee generates -419% less net income/profit than industry average revenue per employee
-1.640971666
Assets/Capital per employee
Each employee generates -164% less free cash flow than industry average revenue per employee
-1.640971666
Research & Development (R&D) Analysis
0.13%
-2.007324631
Competitors/Peer firms of
Medical Devices
$50.49
XOMA CORPORATION (XNAS:XOMA)
NEURONETICS, INC. (XNAS:STIM)
CARDIFF ONCOLOGY, INC. (XNAS:CRDF)
AVROBIO, INC. (XNAS:AVRO)
FREQUENCY THERAPEUTICS, INC. (XNAS:FREQ)
AEGLEA BIOTHERAPEUTICS, INC. (XNAS:AGLE)
VERONA PHARMA PLC. (XNAS:VRNA)
ATRECA, INC. (XNAS:BCEL)
Current Analyst Ratings
$0.83
Strong buy�0%
Buy�4%
Hold�4%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
44.90M
10.53M
306%
1.95M
10.06M
21.30M
11.25M
-
33.79M
-
-
1.51M
112%
699.62K
9.35K
98%
699.62K
Statement of Cash Flow
Date:
Period:
2.49M
Differed Income Tax :
433.93K
Stock Based Compensation :
- 52.04K
Change in Working Capital :
453.36K
Accounts Receivables:
- 1907.35K
Other Working Capital:
186.34K
Other Non-Cash Items:
- 119.87K
Net Cash Provided by Operating Activities:
11.58K
Investments in PP&E:
1.43M
Net Acquisitions:
- 183.35K
Purchases of Investments:
-
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
50.45M
500.09K
50.95M
6.51M
4.35M
3.71M
65.51M
4.56M
-
1.33M
-
808.02K
172.27K
6.88M
-
72.39M
1.14M
280.70K
122.46K
2.59M
2.25M
6.25M
2.13M
-
3.60M
-
9.85M
1.26K
36.92M
6.1K
Value
23.25M
-
62.55M
72.39M
-
2.41M
-
-
- 241.34K
- 424.69K
-
-
-
- 12559.13K
4.57K
- 12554.56K
-
- 11553.07K
50.45M
62.00M
1.43M
- 424.69K
Our Proprietary Portfolio Rating
Our Rating:
-117.8203758
Price Forecast/Expected Price in Next 5 Years of
Medical Devices
2023
2024
2025
2026
2027
38.29312929
$38.29
$41.03
$43.97
$47.12